Cipro XR (Ciprofloxacin, BAYQ3939)
DrugCiprofloxacin XR 1000 mg orally once a day
NCT Number: NCT00668122
To assess and compare the efficacy and safety of ciprofloxacin extended-release (CIPRO XR) tablet 1000 mg PO once-daily (OD) versus ciprofloxacin immediate-release (CIPRO IR) tablet 500 mg PO twice-daily (BID) for 7-14 days in patients with complicated and/or nosocomial urinary tract infections (cUTI).
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Monza, Milano, Italy
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
The primary diagnosis in this clinical trial was cUTI in men or non-pregnant women over 18 years of age. Other main inclusion criteria:
Exclusion criteria
Diagnosis of pyelonephritis supported by clinical signs/symptoms of fever (>38°C orally), chills and flank pain (all 3 signs/symptoms must be present).
Ciprofloxacin XR 1000 mg orally once a day
Ciprofloxacin IR 500 mg orally twice a day
Time frame: 5-9 days
Time frame: 7-14 days
Time frame: 28-42 days
Time frame: 7-14 days
Time frame: 5-9 days
Time frame: 28-42 days
Time frame: 28-42 days
Bayer
Industry
Efficacy and Safety of Ciprofloxacin Extended-Release 1000 mg Once-Daily Versus Ciprofloxacin Immediate-Release 500 mg Twice-Daily Given 7-14 Days in Patients With Complicated Urinary Tract Infections: Prospective, Randomized, Double-Blind Trial.
Acronym: EMERON
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06059846
Acute Pyelonephritis, Female Urogenital Diseases
Miami, Florida, United States
View Trial DetailsNCT01388413
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Garches, France
View Trial DetailsNCT05880602
Disease Attributes, Female Urogenital Diseases
Taichung, Taiwan
View Trial DetailsNCT04502095
Bladder Carcinoma, Female Urogenital Diseases
Buffalo, New York, United States
View Trial Details